Biotech, cancer, Inflammation Luke Timmerman wrote: Some members of the band that pumped out a one-hit wonder at Icos are getting back together to see if they can produce at least one more hit at Seattle-based Calistoga Pharmaceuticals. Calistoga has been building up its management team over the pas...

Biotech, VC, Life Sciences Luke Timmerman wrote: There are easier things to do these days than trying to organize a biotech investing conference in Seattle. The local cluster has taken its share of body blows, the weather is usually pretty gray in late winter, and investors aren’t in the mood ...

Or: why the internet can be sweet for watching sports. Also: how easy it is to screw it up. I’ve recently become rather addicted to web video, but not in the viral/YouTube sense. In fact, I hardly ever look at youtube without a recommendation from a friend. But with Hulu, Netflix, and iTunes o...

Live video is a slam dunk for sporting events, bringing in major viewership the Olympics and golf’s U.S. Open and basketball’s March Madness, and significant paying audiences for sports from baseball to basketball to hockey to cricket. One sport that gets hardly any oldteevee love whatso...

Biotech, Drugs, Life Sciences Stewart Lyman wrote: Seattle’s biotech community used to be among the top-ranked in the nation. But as some 2,500 layoffs have piled up in the local biotech sector since 2002, Seattle has tumbled in the rankings. We need to face up to this fact first, before we ca...

Biotech, cancer, deals Luke Timmerman wrote: The recession will surely kill off some biotech companies that lack hard cash and the hard data that shows their experimental drugs can improve patients’ lives. But after I heard Seattle Genetics CEO Clay Siegall tell the story of how his company ra...

Biotech, acquisitions, Autoimmune Luke Timmerman wrote: Pfizer rocked the business world yesterday with its $68 billion bid to acquire Madison, NJ-based Wyeth (NYSE: WYE), and the ripple effect was felt here in the Northwest. Nobody in town has a bigger stake in this deal than Seattle-based Trubion ...

Biotech, VC, Analysis Luke Timmerman wrote: Tom Ranken is the first to admit he can get a bit ornery on the subject of venture capital in the Northwest. “It used to make me foam at the mouth when VCs would say there’s plenty of money out there and all the good ideas get funded,” he...

Biotech, Software, Web 2.0 Luke Timmerman wrote: Richard Gayle is one of those rare individuals who can really carry a conversation with a molecular biologist and a software developer. He’s a Caltech-trained biochemist, with 16 years of experience at Seattle-based Immunex. While doing his wet-...

Biotech, Life Sciences, events Luke Timmerman wrote: Washington state doesn’t do much Texas-style boasting, and the state’s economic development promoters have never tossed around big bucks to crow about the biotechnology cluster here. Case in point: how many of you know that the world&#...